Citations (66)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
David J. Craik & Meng-Wei Kan. (2021) How can we improve peptide drug discovery? Learning from the past. Expert Opinion on Drug Discovery 16:12, pages 1399-1402.
Read now
Read now
Hongchao Pan, Yunnan Su, Yini Xie, Weiyong Wang, Wanli Qiu, Wei Chen, Wenying Lu, Zhao Lu, Weiwei Wang & Anquan Shang. (2020) Everestmab, a novel long-acting GLP-1/anti GLP-1R nanobody fusion protein, exerts potent anti-diabetic effects. Artificial Cells, Nanomedicine, and Biotechnology 48:1, pages 854-866.
Read now
Read now
Khyati Girdhar, Budheswar Dehury, Mahender Kumar Singh, Vineeth P. Daniel, Abhinav Choubey, Surbhi Dogra, Sunil Kumar & Prosenjit Mondal. (2019) Novel insights into the dynamics behavior of glucagon-like peptide-1 receptor with its small molecule agonists. Journal of Biomolecular Structure and Dynamics 37:15, pages 3976-3986.
Read now
Read now
Qiang Du, Yan-Jun Wang, Sheng Yang & Ping Han. (2015) Clinical utility and patient considerations in the use of the sitagliptin–metformin combination in Chinese patients. Patient Preference and Adherence 9, pages 281-287.
Read now
Read now
Min Joo Kim, Ok Kyong Choi, Kyung Sil Chae, Hakmo Lee, Sung Soo Chung, Dong-Sik Ham, Ji-Won Kim, Kun-Ho Yoon, Kyong Soo Park & Hye Seung Jung. (2015) Autophagy deficiency in β cells blunts incretin-induced suppression of glucagon release from α cells. Islets 7:5.
Read now
Read now
Meng-Wong Taing, Felicity J Rose & Jonathan P Whitehead. (2014) GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?. Drug Design, Development and Therapy 8, pages 677-688.
Read now
Read now
Anthony J. Saviola, María E. Peichoto & Stephen P. Mackessy. (2014) Rear-fanged snake venoms: an untapped source of novel compounds and potential drug leads. Toxin Reviews 33:4, pages 185-201.
Read now
Read now
Articles from other publishers (59)
Jingmin Cai, Linquan Zang, Xueman Wu, Zhiwen Liang, Ke Zheng, Lin Zhao & Huangjin Li. (2024) The construction of long-acting exendin-4 analog and its hypoglycemic effect in diabetic mice. Protein Expression and Purification 213, pages 106373.
Crossref
Crossref
Doaa A. Zaky, Dalaal M. Abdallah & Hanan S. El-Abhar. (2023) Intranasal Exendin-4 modifies necroptosis-mediated innate immune response to combat septic encephalopathy in rats: Role of mTORC1 in immunogenic and tolerogenic cell demise. European Journal of Pharmacology 961, pages 176191.
Crossref
Crossref
Niraj Kumar Singh, Ashini Singh, Mini Varshney & Ritik Agrawal. (2023) A Research Update on Exendin-4 as a Novel Molecule Against
Parkinson’s Disease. Current Molecular Medicine 23:9, pages 889-900.
Crossref
Crossref
A.H.H. Siddique & P.P. Kale. (2023) Importance of glucose and its metabolism in neurodegenerative disorder, as well as the combination of multiple therapeutic strategies targeting α-synuclein and neuroprotection in the treatment of Parkinson's disease. Revue Neurologique.
Crossref
Crossref
Jianhua Lai, Xingkai Zhao, Dongting Zhangsun, Yong Wu & Sulan Luo. (2023) Synthesis of Con-Ins GIe with high yield and cost-effectiveness using partially directed synthesis. Tetrahedron 139, pages 133441.
Crossref
Crossref
Eleni A. Karavia, Panagiota C. Giannopoulou, Vassiliki Konstantinopoulou, Katerina Athanasopoulou, Theodosios D. Filippatos, Demosthenes Panagiotakos & Kyriakos E. Kypreos. (2023) Medicines for Obesity: Appraisal of Clinical Studies with Grading of Recommendations, Assessment, Development, and Evaluation Tool. Nutrients 15:3, pages 606.
Crossref
Crossref
Lei Wang, Nanxi Wang, Zhibin Yan, Zhifeng Huang & Caiyun Fu. 2023. Privileged Scaffolds in Drug Discovery. Privileged Scaffolds in Drug Discovery
795
815
.
Lorenzo Pacini, Annunziata D’Ercole, Anna Maria Papini, Daniele Bani, Silvia Nistri & Paolo Rovero. (2022) Porcine Relaxin but Not Serelaxin Shows Residual Bioactivity after In Vitro Simulated Intestinal Digestion—Clues for the Development of New Relaxin Peptide Agonists Suitable for Oral Delivery. International Journal of Molecular Sciences 24:1, pages 48.
Crossref
Crossref
J. Michael Conlon, Finbarr P.M. O’Harte & Peter R. Flatt. (2022) Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy – A review. Peptides 147, pages 170706.
Crossref
Crossref
Anna Roberts, Phyllis Phuah, Sijing Cheng & Kevin G. Murphy. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
344
372
.
Guilherme Rabelo Coelho, Daiane Laise da Silva, Emidio Beraldo-Neto, Hugo Vigerelli, Laudiceia Alves de Oliveira, Juliana Mozer Sciani & Daniel Carvalho Pimenta. (2021) Neglected Venomous Animals and Toxins: Underrated Biotechnological Tools in Drug Development. Toxins 13:12, pages 851.
Crossref
Crossref
Luba Yammine, Charles E Green, Thomas R Kosten, Constanza de Dios, Robert Suchting, Scott D Lane, Christopher D Verrico & Joy M Schmitz. (2021) Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: A Pilot Randomized Controlled Trial. Nicotine & Tobacco Research 23:10, pages 1682-1690.
Crossref
Crossref
Dharmendra Kumar Khatri, Amey Kadbhane, Monica Patel, Shweta Nene, Srividya Atmakuri, Saurabh Srivastava & Shashi Bala Singh. (2021) Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders. Current Research in Pharmacology and Drug Discovery 2, pages 100022.
Crossref
Crossref
Helen C. Mendel, Quentin Kaas & Markus Muttenthaler. (2020) Neuropeptide signalling systems – An underexplored target for venom drug discovery. Biochemical Pharmacology 181, pages 114129.
Crossref
Crossref
Albert Y. Hung & Michael A. Schwarzschild. (2020) Approaches to Disease Modification for Parkinson’s Disease: Clinical Trials and Lessons Learned. Neurotherapeutics 17:4, pages 1393-1405.
Crossref
Crossref
E.L. Schneider, R. Reid, D.G. Parkes, T.A. Lutz, G.W. Ashley & D.V. Santi. (2020) A once-monthly GLP-1 receptor agonist for treatment of diabetic cats. Domestic Animal Endocrinology 70, pages 106373.
Crossref
Crossref
Mohamed E.I. Badawy. 2020. Bioactive Natural Products. Bioactive Natural Products
321
364
.
Xinwang Yang, Ying Wang, Chunyun Wu & Eng-Ang Ling. (2019) Animal Venom Peptides as a Treasure Trove for New Therapeutics Against Neurodegenerative Disorders. Current Medicinal Chemistry 26:25, pages 4749-4774.
Crossref
Crossref
Thomas GuttusoJr.Jr., Kelly L. Andrzejewski, David G. Lichter & Julie K. Andersen. (2019) Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium. Journal of the Neurological Sciences 402, pages 121-130.
Crossref
Crossref
A.R. Pinho, A. Fortuna, A. Falcão, A.C. Santos, R. Seiça, C. Estevens, F. Veiga & A.J. Ribeiro. (2019) Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices. Journal of Pharmaceutical Analysis 9:3, pages 143-155.
Crossref
Crossref
Yilin Tang, Ke Yang, Jue Zhao, Xiaoniu Liang & Jian Wang. (2019) Evidence of Repurposing Drugs and Identifying Contraindications from Real World Study in Parkinson’s Disease. ACS Chemical Neuroscience 10:2, pages 954-963.
Crossref
Crossref
Enrico Bagnoli & Una FitzGerald. (2019) Mitral cells and the glucagon‐like peptide 1 receptor: The sweet smell of success?. European Journal of Neuroscience 49:4, pages 422-439.
Crossref
Crossref
Daoqi Tang, Hong Tian, Jicheng Wu, Jiaxiao Cheng, Cheng Luo, Wenbo Sai, Xiaoda Song, Xiangdong Gao & Wenbing Yao. (2018) C-terminal site-specific PEGylated Exendin-4 analog: A long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db/db mice. Journal of Pharmacological Sciences 138:1, pages 23-30.
Crossref
Crossref
Dilan Athauda & Thomas Foltynie. (2018) Drug Repurposing in Parkinson’s Disease. CNS Drugs 32:8, pages 747-761.
Crossref
Crossref
Dilan Athauda & Thomas Foltynie. (2018) Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease. Neuropharmacology 136, pages 260-270.
Crossref
Crossref
Dilan Athauda, Kate MaclaganNatalia Budnik, Luca Zampedri, Steve HibbertSimon S. Skene, Kashfia ChowdhuryIciar Aviles-Olmos, Patricia Limousin & Thomas Foltynie. (2018) What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson’s Disease: A Post Hoc Analysis. Journal of Parkinson's Disease 8:2, pages 247-258.
Crossref
Crossref
Patrick J. Knerr, Brian Finan, Vasily Gelfanov, Diego Perez-Tilve, Matthias H. Tschöp & Richard D. DiMarchi. (2018) Optimization of peptide-based polyagonists for treatment of diabetes and obesity. Bioorganic & Medicinal Chemistry 26:10, pages 2873-2881.
Crossref
Crossref
Antoine Henninot, James C. Collins & John M. Nuss. (2017) The Current State of Peptide Drug Discovery: Back to the Future?. Journal of Medicinal Chemistry 61:4, pages 1382-1414.
Crossref
Crossref
J. Michael Conlon, Milena Mechkarska, Yasser H. Abdel-Wahab & Peter R. Flatt. (2018) Peptides from frog skin with potential for development into agents for Type 2 diabetes therapy. Peptides 100, pages 275-281.
Crossref
Crossref
Luba Yammine, Thomas R. Kosten, Paul M. Cinciripini, Charles E. Green, Janet C. Meininger, Jennifer A. Minnix & Thomas F. Newton. (2018) Exenatide once weekly for smoking cessation. Medicine 97:2, pages e9567.
Crossref
Crossref
Ariadna Lobo-Ruiz & Judit Tulla-Puche. 2018. Peptide Applications in Biomedicine, Biotechnology and Bioengineering. Peptide Applications in Biomedicine, Biotechnology and Bioengineering
23
49
.
Srividya Vasu, Opeolu O. Ojo, R. Charlotte Moffett, J. Michael Conlon, Peter R. Flatt & Yasser H. A. Abdel-Wahab. (2017) Anti-diabetic actions of esculentin-2CHa(1–30) and its stable analogues in a diet-induced model of obesity-diabetes. Amino Acids 49:10, pages 1705-1717.
Crossref
Crossref
Eric L. Schneider, Brian R. Hearn, Samuel J. Pfaff, Ralph Reid, David G. Parkes, Niels Vrang, Gary W. Ashley & Daniel V. Santi. (2017) A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration of a GLP-1 Receptor Agonist. ACS Chemical Biology 12:8, pages 2107-2116.
Crossref
Crossref
Bhargav Prasad Kodaganti, Pavithra Mukunda, Pravinkumar Dakshinamurthy, Yogendra Manjunath, Bharath Ravindra Shenoy, Veeresha Kamanagowda, Bairavabalakumar Natarajan, Amol Maliwalave, Divya Unnikrishnan, Sathyabalan Murugesan, Vivek Halan, Maloy Ghosh & Sunit Maity. (2017) Microbial expression of Exendin-4 analog and its efficacy in mice model. Biologicals 48, pages 82-91.
Crossref
Crossref
Srividya Vasu, Mary K McGahon, R Charlotte Moffett, Tim M Curtis, J Michael Conlon, Yasser H A Abdel-Wahab & Peter R Flatt. (2017) Esculentin-2CHa(1–30) and its analogues: stability and mechanisms of insulinotropic action. Journal of Endocrinology 232:3, pages 423-435.
Crossref
Crossref
Samuel D. Robinson & Helena Safavi-Hemami. (2016) Insulin as a weapon. Toxicon 123, pages 56-61.
Crossref
Crossref
Yan Pang, Jinyao Liu, Yizhi Qi, Xinghai Li & Ashutosh Chilkoti. (2016) A Modular Method for the High-Yield Synthesis of Site-Specific Protein-Polymer Therapeutics. Angewandte Chemie International Edition 55:35, pages 10296-10300.
Crossref
Crossref
Yan Pang, Jinyao Liu, Yizhi Qi, Xinghai Li & Ashutosh Chilkoti. (2016) A Modular Method for the High-Yield Synthesis of Site-Specific Protein-Polymer Therapeutics. Angewandte Chemie 128:35, pages 10452-10456.
Crossref
Crossref
Pauline Bonvin, Christine A. Power & Amanda E. I. Proudfoot. (2016) Evasins: Therapeutic Potential of a New Family of Chemokine-Binding Proteins from Ticks. Frontiers in Immunology 7.
Crossref
Crossref
Dilan Athauda & Thomas Foltynie. (2016) The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. Drug Discovery Today 21:5, pages 802-818.
Crossref
Crossref
Dinesh K. Srinivasan, Opeolu O. Ojo, Bosede O. Owolabi, J. Michael Conlon, Peter R. Flatt & Yasser H. A. Abdel-Wahab. (2015) [I10W]tigerinin-1R enhances both insulin sensitivity and pancreatic beta cell function and decreases adiposity and plasma triglycerides in high-fat mice. Acta Diabetologica 53:2, pages 303-315.
Crossref
Crossref
Yeray Brito-Casillas, Laura López-Ríos, Julia C. Wiebe, Clara Muñoz-Mediavilla, Francisco J. Nóvoa-Mogollón, Antonio Ojeda & Ana M. Wägner. (2016) Uromastyx acanthinura as a natural treatment in a mouse model of type 2 diabetes. Endocrinología y Nutrición 63:1, pages 13-18.
Crossref
Crossref
Yeray Brito-Casillas, Laura López-Ríos, Julia C. Wiebe, Clara Muñoz-Mediavilla, Francisco J. Nóvoa-Mogollón, Antonio Ojeda & Ana M. Wägner. (2016) Uromastyx acanthinura as a natural treatment in a mouse model of type 2 diabetes. Endocrinología y Nutrición (English Edition) 63:1, pages 13-18.
Crossref
Crossref
E V Gurevich & V V Gurevich. (2015) Beyond traditional pharmacology: new tools and approaches. British Journal of Pharmacology 172:13, pages 3229-3241.
Crossref
Crossref
Chunxia Zhao, Chunping Qiao, Ru-Hang Tang, Jiangang Jiang, Jianbin Li, Carrie Bette Martin, Karen Bulaklak, Juan Li, Dao Wen Wang & Xiao Xiao. (2015) Overcoming Insulin Insufficiency by Forced Follistatin Expression in β -cells of db/db Mice. Molecular Therapy 23:5, pages 866-874.
Crossref
Crossref
Kristian W. Sanggaard, Thomas F. Dyrlund, Line R. Thomsen, Tania A. Nielsen, Lars Brøndum, Tobias Wang, Ida B. Thøgersen & Jan J. Enghild. (2015) Characterization of the gila monster (Heloderma suspectum suspectum) venom proteome. Journal of Proteomics 117, pages 1-11.
Crossref
Crossref
Helena Safavi-HemamiJoanna GajewiakSanthosh KaranthSamuel D. RobinsonBeatrix UeberheideAdam D. DouglassAmnon SchlegelJulita S. ImperialMaren WatkinsPradip K. BandyopadhyayMark Yandell, Qing LiAnthony W. Purcell, Raymond S. NortonLars EllgaardBaldomero M. Olivera. (2015) Specialized insulin is used for chemical warfare by fish-hunting cone snails. Proceedings of the National Academy of Sciences 112:6, pages 1743-1748.
Crossref
Crossref
Shaocong Hou, Caina Li, Yi Huan, Shuainan Liu, Quan Liu, Sujuan Sun, Qian Jiang, Chunming Jia & Zhufang Shen. (2015) Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice. Journal of Diabetes Research 2015, pages 1-17.
Crossref
Crossref
Dilan Athauda & Thomas Foltynie. (2014) The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nature Reviews Neurology 11:1, pages 25-40.
Crossref
Crossref
Steven M. Ogbourne & Peter G. Parsons. (2014) The value of nature's natural product library for the discovery of New Chemical Entities: The discovery of ingenol mebutate. Fitoterapia 98, pages 36-44.
Crossref
Crossref
Benjamin J Lamont & Sofianos Andrikopoulos. (2014) Hope and fear for new classes of type 2 diabetes drugs: is there preclinical evidence that incretin-based therapies alter pancreatic morphology?. Journal of Endocrinology 221:1, pages T43-T61.
Crossref
Crossref
Krystyna Tatarkiewicz, Emmanuel J. Sablan, Clara J. Polizzi, Christiane Villescaz & David G. Parkes. (2014) Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 306:7, pages R490-R498.
Crossref
Crossref
K. Tatarkiewicz, C. Polizzi, C. Villescaz, L. J. D'Souza, Y. Wang, S. Janssen & D. G. Parkes. (2013) Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice. Diabetes, Obesity and Metabolism 16:4, pages 376-380.
Crossref
Crossref
Donald H. Maurice, Hengming Ke, Faiyaz Ahmad, Yousheng Wang, Jay Chung & Vincent C. Manganiello. (2014) Advances in targeting cyclic nucleotide phosphodiesterases. Nature Reviews Drug Discovery 13:4, pages 290-314.
Crossref
Crossref
Thomas Forest, Daniel Holder, Adam Smith, Caron Cunningham, Xiaorui Yao, Markus Dey, Clay Frederick & Srinivasa Prahalada. (2014) Characterization of the Exocrine Pancreas in the Male Zucker Diabetic Fatty Rat Model of Type 2 Diabetes Mellitus Following 3 Months of Treatment With Sitagliptin. Endocrinology 155:3, pages 783-792.
Crossref
Crossref
Paul L. McCormack. (2014) Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus. Drugs 74:3, pages 325-351.
Crossref
Crossref
Joanne Bronson, Amelia Black, Murali Dhar, Bruce Ellsworth & J. Robert Merritt. 2014.
437
508
.
Daniel J. Drucker. (2013) Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls. Diabetes 62:10, pages 3316-3323.
Crossref
Crossref
Cicero L. T. Chang, Yenshou Lin, Arlene P. Bartolome, Yi-Ching Chen, Shao-Chih Chiu & Wen-Chin Yang. (2013) Herbal Therapies for Type 2 Diabetes Mellitus: Chemistry, Biology, and Potential Application of Selected Plants and Compounds. Evidence-Based Complementary and Alternative Medicine 2013, pages 1-33.
Crossref
Crossref